Literature DB >> 19727297

Treatment of fibromyalgia.

Elisa F Cascade1, Amir H Kalali, Nikhil D Nihalani, Thomas L Schwartz.   

Abstract

In this article, we investigate the range of treatments prescribed for fibromyalgia. The data suggest that the majority of those treated, 72 percent, receive only one pharmaceutical. An additional 18 percent of patients were prescribed two products and 10% received three products. Pregabalin (Lyrica(R)) monotherapy was the most commonly prescribed regimen (28% of patients) followed by duloxetine (Cymbalta(R)) monotherapy (6%). From a therapeutic class perspective, fibromyalgia patients received pain therapies (42%), antiepileptics (40%), antidepressants (28%), muscle relaxants (14%), and sleep agents (8%). An expert commentary is also included.

Entities:  

Keywords:  duloxetine; fibromyalgia; gabapentin; milnacipran; pharmacology; pregabalin

Year:  2008        PMID: 19727297      PMCID: PMC2710103     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  9 in total

1.  Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States.

Authors:  R C Lawrence; C G Helmick; F C Arnett; R A Deyo; D T Felson; E H Giannini; S P Heyse; R Hirsch; M C Hochberg; G G Hunder; M H Liang; S R Pillemer; V D Steen; F Wolfe
Journal:  Arthritis Rheum       Date:  1998-05

Review 2.  Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?

Authors:  David G S Perahia; Yili L Pritchett; Durisala Desaiah; Joel Raskin
Journal:  Int Clin Psychopharmacol       Date:  2006-11       Impact factor: 1.659

3.  Use of complementary and alternative medical therapies by patients referred to a fibromyalgia treatment program at a tertiary care center.

Authors:  Dietlind L Wahner-Roedler; Peter L Elkin; Ann Vincent; Jeffrey M Thompson; Terry H Oh; Laura L Loehrer; Jayawant N Mandrekar; Brent A Bauer
Journal:  Mayo Clin Proc       Date:  2005-01       Impact factor: 7.616

4.  Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.

Authors:  Stephen K Brannan; Craig H Mallinckrodt; Eileen B Brown; Madelaine M Wohlreich; John G Watkin; Alan F Schatzberg
Journal:  J Psychiatr Res       Date:  2005-01       Impact factor: 4.791

5.  Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review.

Authors:  D A Fishbain; R Cutler; H L Rosomoff; R S Rosomoff
Journal:  Pain Med       Date:  2000-12       Impact factor: 3.750

6.  The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia.

Authors:  Lesley M Arnold; Leslie J Crofford; Susan A Martin; James P Young; Uma Sharma
Journal:  Pain Med       Date:  2007 Nov-Dec       Impact factor: 3.750

7.  The prevalence and characteristics of fibromyalgia in the general population.

Authors:  F Wolfe; K Ross; J Anderson; I J Russell; L Hebert
Journal:  Arthritis Rheum       Date:  1995-01

8.  The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee.

Authors:  F Wolfe; H A Smythe; M B Yunus; R M Bennett; C Bombardier; D L Goldenberg; P Tugwell; S M Campbell; M Abeles; P Clark
Journal:  Arthritis Rheum       Date:  1990-02

9.  Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.

Authors:  Joel Raskin; Curtis G Wiltse; Alan Siegal; Javaid Sheikh; Jimmy Xu; James J Dinkel; Benjamin T Rotz; Richard C Mohs
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.